Bridgewater Chapter Upcoming Events Join PCCI

Monday, June 11, 2007


DSX Therapeutic LLC

A Biotechnology Company Focused on the Area of Sepsis

Presenter: Joseph M. Marasco, President of DSX Therapeutics



DSX Therapeutics aims to capture a significant fraction of a $75 billion per year market based upon new enabling technologies it has discovered, developed and patented. These new technologies have led to unique new products to meet existing underserved market needs for rapid diagnostic tests and effective therapeutic treatments for sepsis and severe sepsis. The mission of DSX Therapeutics is to commercialize the first effective treatment for sepsis and severe sepsis, aSeptiMab*, and the first rapid diagnostic test that is able to predict early the onset of sepsis. DSX also intends to expand its unique iNos therapies and diagnostics into other inflammatory disorders.


Hospital-acquired infections (nosocomial infections) are preventable adverse patient events that affect approximately 2 million people in the U.S. every year. One of the leading causes of morbidity and mortality in the hospital, particularly in the ICU, is sepsis. Each year, at least 7 million patients enter into the early stages of sepsis; this results in more than 750,000 deaths per year.


Sepsis is not an infection; it is a person's system-wide response to an infection, which in many individuals poses life threatening risk of organ dysfunction, damage and death. With this insidious pathology, the body attacks itself. Micro-organisms such as bacteria and fungi, can invade the body through wounds and IV lines, grow out of control, and initiate the hyperinflammatory response that is a distinctive characteristic of sepsis and severe sepsis.


The ability to diagnose sepsis rapidly and accurately in its early stages remains one of the biggest challenges faced by hospitals. Early detection is critical to improved outcomes for patients and more efficient use of health care resources.



4 Major Issues


  1. We believe we should license our diagnostic test separately from the preclinical therapeutic. The diagnostic has completed three human proof of concept trials for early indication of sepsis. Could there be any disadvantage, aside from a delay of licensing revenue, in "saving" the test as a package when we do have suitable clinical data on the therapeutic?
  2. What would be the most efficient method to seek out board members? (We are likely to stay private, but there is a real possibility of entering the public domain soon in Canada, which of course has an immediate impact on the type of personnel we enlist. In either case, we would like to expand our board soon).
  3. We have heard, but not yet explored, that the NIH Foundation has pools of money to be applied for Phase I clinical trials of selected projects. Does anyone have experience with this entity?
  4. Phase I clinical trials for cancer drugs have sometimes yielded confirmed efficacy data, according to a well known CRO we've been speaking with. Does anyone in the group have experience with this, or can someone describe the methods in setting up safety trials that yield some type of efficacy data? (Our therapeutic area is not cancer).





6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Joseph M. Marasco, President of DSX Therapeutics, will deliver the company's "Elevator" Pitch to the Group

8:20 - Panel addresses 4 major issues for DSX Therapeutics

9:00 - Open discussion: members and guests



<Top of the page>




Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


None available at this time


None available at this time


None available at this time

Contact Info:

Not Available


Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc